Notice of Proposed Sale · 144
Caris Life Sciences, Inc.
CAINASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CARIS LIFE SCIENCES, INC.
- Issuer CIK
- 0002019410
- SEC file number
- 001-42706
- Phone
- (866) 771-8946
- Person for whose account securities are to be sold
- GEORGE H POSTE
- Relationships to issuer
- Director
- Street
- 750 W JOHN CARPENTER FREEWAY
- Street (continued)
- SUITE 800
- City
- IRVING
- State / country code
- TX
- Postal code
- 75039
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 20,000 | 325,000.00 | 282,680,695 | 08/03/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 08/03/2026 | Stock Option Exercise | Issuer | 20,000 | N | 08/03/2026 | Cash |
Prior-sale reporting
- Nothing to report for the preceding three months
- Y
Notice signature
- Notice date
- 08/03/2026
- Signed
- /s/ George Poste
Company context
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.